NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (168)	1/19/1999 2:43:00 PM
From: Steve Lokness	Read Replies (2) of 613

Scott; If you are asking me why I left out MLNM and VICL, it is because I was just trying to mention some of those that I felt have some growth potential - or could be discussed so that we could learn more about small under-followed companies. In fact I didn't even mention the sub group of biotech into sequencing. Even though this group has bunches of cash, I have trouble seeing where the income will be coming from. After sequencing, I think the next natural step might be protein mapping - that is how the gene information can be used in a more overall understanding of how disease works. The big winners I think will be the gene therapy companies, but that is yet off in the future - but definately getting closer. Does make an interesting sub group of biotechs though doesn't it? Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next